-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
DermTech, Inc. (NASDAQ:DMTK) Forecasted to Earn Q3 2022 Earnings of ($0.98) Per Share
DermTech, Inc. (NASDAQ:DMTK) Forecasted to Earn Q3 2022 Earnings of ($0.98) Per Share
DermTech, Inc. (NASDAQ:DMTK – Get Rating) – Equities research analysts at Oppenheimer boosted their Q3 2022 earnings per share estimates for shares of DermTech in a report released on Tuesday, August 16th. Oppenheimer analyst F. Brisebois now forecasts that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.06). Oppenheimer has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for DermTech's current full-year earnings is ($4.02) per share. Oppenheimer also issued estimates for DermTech's Q4 2022 earnings at ($0.97) EPS, FY2022 earnings at ($3.95) EPS, Q1 2023 earnings at ($1.02) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.84) EPS and FY2023 earnings at ($3.53) EPS.
Get DermTech alerts:A number of other brokerages have also weighed in on DMTK. Craig Hallum decreased their price objective on DermTech from $37.00 to $18.00 in a report on Tuesday, August 9th. BTIG Research cut their target price on DermTech from $19.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, August 15th. Lake Street Capital cut their target price on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Finally, Cowen cut their target price on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th.
DermTech Price Performance
Shares of NASDAQ:DMTK opened at $5.71 on Friday. The business's 50 day moving average price is $6.47 and its 200-day moving average price is $9.37. The firm has a market capitalization of $171.53 million, a price-to-earnings ratio of -1.60 and a beta of 1.40. DermTech has a 1 year low of $4.18 and a 1 year high of $38.97.Institutional Trading of DermTech
A number of hedge funds and other institutional investors have recently modified their holdings of DMTK. Financial Management Professionals Inc. purchased a new position in DermTech during the 2nd quarter valued at about $26,000. Wolverine Asset Management LLC purchased a new position in DermTech during the 4th quarter valued at about $43,000. Wedbush Securities Inc. purchased a new position in DermTech during the 2nd quarter valued at about $58,000. Amalgamated Bank purchased a new position in DermTech during the 1st quarter valued at about $58,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of DermTech in the 2nd quarter valued at about $60,000. 75.12% of the stock is owned by institutional investors and hedge funds.
About DermTech
(Get Rating)
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
Further Reading
- Get a free copy of the StockNews.com research report on DermTech (DMTK)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.
DermTech, Inc. (NASDAQ:DMTK – Get Rating) – Equities research analysts at Oppenheimer boosted their Q3 2022 earnings per share estimates for shares of DermTech in a report released on Tuesday, August 16th. Oppenheimer analyst F. Brisebois now forecasts that the company will earn ($0.98) per share for the quarter, up from their previous estimate of ($1.06). Oppenheimer has a "Outperform" rating and a $23.00 price objective on the stock. The consensus estimate for DermTech's current full-year earnings is ($4.02) per share. Oppenheimer also issued estimates for DermTech's Q4 2022 earnings at ($0.97) EPS, FY2022 earnings at ($3.95) EPS, Q1 2023 earnings at ($1.02) EPS, Q2 2023 earnings at ($0.85) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.84) EPS and FY2023 earnings at ($3.53) EPS.
德姆泰克公司(纳斯达克代码:DMTK-GET Rating)-在8月16日星期二发布的一份报告中,奥本海默的股票研究分析师上调了对德姆泰克公司2022年第三季度每股收益的预期。奥本海默分析师F.Brisebois现在预测,该公司本季度每股收益为0.98美元,高于此前预测的1.06美元。奥本海默对该股的评级为“跑赢大盘”,目标价为23.00美元。对德美科技目前全年收益的普遍预期为每股4.02美元。奥本海默还发布了对DermTech 2022财年第四季度每股收益(0.97美元)、2022财年每股收益(3.95美元)、2023年第一季度每股收益(1.02美元)、2023年第二季度每股收益(0.85美元)、2023年第三季度每股收益(0.85美元)、2023年第四季度每股收益(0.84美元)和2023财年每股收益(3.53美元)的预期。
A number of other brokerages have also weighed in on DMTK. Craig Hallum decreased their price objective on DermTech from $37.00 to $18.00 in a report on Tuesday, August 9th. BTIG Research cut their target price on DermTech from $19.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, August 15th. Lake Street Capital cut their target price on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Finally, Cowen cut their target price on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th.
其他一些券商也加入了DMTK的行列。Craig Hallum在8月9日星期二的一份报告中将他们对DermTech的目标价从37.00美元下调至18.00美元。BTIG Research在8月15日周一的一份研究报告中将其对DermTech的目标价从19.00美元下调至15.00美元,并为该公司设定了“买入”评级。Lake Street Capital在8月9日周二的一份研究报告中将DermTech的目标价从34.00美元下调至14.00美元。最后,考恩在5月4日星期三的一份研究报告中将其对DermTech的目标价从33.00美元下调至20.00美元。
DermTech Price Performance
DemTech性价比
Institutional Trading of DermTech
DemTech的制度性交易
A number of hedge funds and other institutional investors have recently modified their holdings of DMTK. Financial Management Professionals Inc. purchased a new position in DermTech during the 2nd quarter valued at about $26,000. Wolverine Asset Management LLC purchased a new position in DermTech during the 4th quarter valued at about $43,000. Wedbush Securities Inc. purchased a new position in DermTech during the 2nd quarter valued at about $58,000. Amalgamated Bank purchased a new position in DermTech during the 1st quarter valued at about $58,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of DermTech in the 2nd quarter valued at about $60,000. 75.12% of the stock is owned by institutional investors and hedge funds.
一些对冲基金和其他机构投资者最近调整了对DMTK的持股。金融管理专业人士公司在第二季度购买了德美泰克的一个新头寸,价值约2.6万美元。金刚狼资产管理有限责任公司在第四季度购买了DermTech的一个新头寸,价值约43,000美元。韦德布什证券公司在第二季度以约58,000美元的价格购买了DermTech的新头寸。合并银行在第一季度购买了DermTech的一个新头寸,价值约58,000美元。最后,法雷奥金融顾问有限责任公司在第二季度购买了价值约6万美元的DermTech新股头寸。75.12%的股票由机构投资者和对冲基金持有。
About DermTech
关于德美科技
(Get Rating)
(获取评级)
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
分子诊断公司DermTech,Inc.开发和销售新的非侵入性基因组测试,以诊断美国的皮肤癌、炎症性疾病和衰老相关疾病。它提供DermTech黑色素瘤测试(DMT),这是一种基因表达测试,可增强对基因组非典型性的早期检测,并有助于排除黑色素瘤和对非典型色素病变进行手术活检的必要性。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on DermTech (DMTK)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- 免费获取StockNews.com关于DermTech的研究报告(DMTK)
- 2家电动汽车供应商在提出意见后上涨
- 应用材料公司业绩显示半导体市场放缓
- MarketBeat:回顾中的一周8/15-8/19
- 近期逆风为Ross Stores带来机遇
- 苹果股价可能再次上涨30%
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.
接受DermTech Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对DermTech和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧